source
- STAT releases AI Prognosis newsletter on health tech leaders' policy discussions in WashingtonSTAT's AI Prognosis newsletter issued a new edition that looks at what health technology executives are saying about policy issues in Washington. The piece was authored by Brittany Trang, a Ph.D.…
- Lilly's triple-agonist retatrutide drives up to 18.8% weight loss, over half of patients fall below obesity thresholdAt the EASD Annual Meeting in Milan, Eli Lilly presented data on its triple‑agonist retatrutide. The trial involved participants with obesity and type 2 diabetes and showed weight reductions of up…